Lillian L. Siu

Research interests

Publications

• Beyond immune checkpoint blockade: emerging immunological strategies

  Nature Reviews Drug Discovery · 2021 · 10.1038/s41573-021-00155-y

• Small molecules, big impact: 20 years of targeted therapy in oncology

  The Lancet · 2020 · 10.1016/s0140-6736(20)30164-1

• Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

  Nature Cancer · 2020 · https://doi.org/10.1038/s43018-020-0096-5

• Circulating tumor DNA and liquid biopsy in oncology

  Nature Cancer · 2020 · 10.1038/s43018-020-0043-5

• Molecular profiling for precision cancer therapies

  Genome Medicine · 2020 · https://doi.org/10.1186/s13073-019-0703-1

• How liquid biopsies can change clinical practice in oncology

  Annals of Oncology · 2019 · 10.1093/annonc/mdz227

• Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.2292

• Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

  JAMA Oncology · 2018 · 10.1001/jamaoncol.2018.4628

• AACR Project GENIE: Powering Precision Medicine through an International Consortium

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-17-0151

• Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

  Genome Medicine · 2016 · https://doi.org/10.1186/s13073-016-0364-2

• Toward understanding and exploiting tumor heterogeneity

  Nature Medicine · 2015 · 10.1038/nm.3915

• Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.58.6412

• Tumour heterogeneity in the clinic

  Nature · 2013 · https://doi.org/10.1038/nature12627

• Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.0164

• Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.2056

• Dose Escalation Methods in Phase I Cancer Clinical Trials

  JNCI Journal of the National Cancer Institute · 2009 · https://doi.org/10.1093/jnci/djp079

• Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.1670

• A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

  British Journal of Cancer · 2006 · https://doi.org/10.1038/sj.bjc.6603419

• Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.51.008

• Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.00.141

• Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2004.00.7542

• Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.06.125

• Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

  Annals of Oncology · 2005 · 10.1093/annonc/mdi310

• Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.12.044

• The statins as anticancer agents.

  PubMed · 2003

• Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2004.06.075

• Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

  Journal of Clinical Oncology · 2001 · https://doi.org/10.1200/jco.2001.19.13.3267

Current projects

No projects listed.